Literature DB >> 8822623

Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene.

A R Fooks1, D Jeevarajah, A Warnes, G W Wilkinson, J C Clegg.   

Abstract

The measles virus (MV) nucleocapsid (N) protein gene has been inserted into a plasmid vector so as to place the gene under the control of the strong constitutive human cytomegalovirus major immediate early promoter. On intramuscular injection of pMV64 DNA into C3H/He mice, seroconversion with increasing titers of N-specific serum IgG antibodies was observed over a period of 3 months. However, when 3-week-old mice were immunized by intramuscular injection of pMV64 in a two-dose schedule, and challenged intracranially with a rodent-adapted measles virus strain (CAM/RB) at 5 weeks of age, no significant protective response was seen. The lack of effective protection evoked by DNA immunization in this model, where MV challenge must take place before 8 weeks of age, may be due to inefficient induction of cell-mediated immunity resulting from expression in muscle tissue, compounded by a relatively slow rise in immune response compared with that seen with the recombinant adenovirus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822623     DOI: 10.1089/vim.1996.9.65

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  3 in total

Review 1.  Genetic vaccines: strategies for optimization.

Authors:  G Gregoriadis
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 2.  Genetic vaccines--a revolution in vaccinology?

Authors:  Z Q Xiang; S Pasquini; Z He; H Deng; Y Wang; M A Blaszczyk-Thurin; H C Ertl
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Neutralizing human Fab fragments against measles virus recovered by phage display.

Authors:  Cristina de Carvalho Nicacio; R Anthony Williamson; Paul W H I Parren; Ake Lundkvist; Dennis R Burton; Ewa Björling
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.